The UHC goals as proposed by the World Health Organization (WHO) is that ‘all’ people and communities are able to access essential services with sufficient quality, while government ensures that the use of such services does not expose the users to financial hardship [11]. This study clearly confirms that Thailand UHC had achieved high level of financial risk protection against catastrophic health spending and impoverishment from health payment by households and reaffirms the negative correlation between public health insurance coverage and incidence of catastrophic payments [6]. The percentage of households in Thailand encountering catastrophic health spending and healthcare impoverishment was on par with several high income countries in Europe, North America and Oceania; for instance, Austria, France and Germany [6, 12].
Several factors synergistically contributed to the financial protection of households against catastrophic health spending and impoverishment.
Firstly, all three public health insurance schemes provide full financial coverage to their members and cover full cost of services to healthcare facilities; hence not allow co-payment or balanced billing from the service users. Full financial coverage for services reduced OOP by households. Also general tax, the sole source of financing UCS and CSMBS, is the most progressive source of health financing as the rich pays higher direct tax in monetary terms than the poor [1]. Full financial coverage is reflected by the percentage of domestic general government health expenditure (GGHE-D) to current health expenditure had increased from 65% in 2002 (when the UCS was launched) to 78% in 2016; while the percentage of OOP to the current health expenditure had reduced from 28–12% during the same period [13]. The lower the proportion of OOP in financing health services is, the lower the incidence of catastrophic health spending and impoverishment incurs [14].
Secondly, benefits package covered by all schemes is comprehensive, without maximum limits of financial coverage and literally no co-payment at point of service, resulting in a massive reduction of OOP by households. The benefits package also applies negative list approach, that is, all interventions are covered except a few exclusion list such as infertility, aesthetic surgery and treatment under research or pilot study [1]. Later when the national capacity in conducting health technology assessment improved, more cost effective interventions were included in the benefits package, which further boosted the financial risk protection [15]. Curative services include medicines in the national list of essential medicines (NLEM). The NLEM was scaled up from the minimum ‘essential medicine list’ with reference to WHO model list to a ‘reimbursement list’ for all three public health insurance schemes since 2003. As of 2017, there are 849 drug items in the current NLEM [16], Table 4.
Table 4
Number of drugs in the national list of essential medicines, by 17 groups
Group no. | Category | No. of drugs |
1 | Gastrointestinal | 39 |
2 | Cardiovascular | 72 |
3 | Respiratory | 30 |
4 | Central nervous systems | 102 |
5 | Infections | 133 |
6 | Endocrine systems | 43 |
7 | Obstetrics and gynaecology | 22 |
8 | Malignant diseases and immuno-suppression | 56 |
9 | Nutrition | 93 |
10 | Musculoskeletal and joint diseases | 24 |
11 | Eye | 41 |
12 | Ears, nose, oropharynx and oral cavity | 42 |
13 | Skin | 47 |
14 | Immunological products and vaccines | 24 |
15 | Anaesthesia | 31 |
16 | Antidotes | 33 |
17 | Contrast media and radiopharmaceuticals | 17 |
Total | 849 |
Source: Food and Drug Administration (FDA), Thailand [16] |
Thirdly, closed end provider payment, notably the dominance of capitation for OP care and Diagnostic Related Group under global budget for IP care applied by the three schemes (except fee for service for CSMBS OP services), results in cost containment which frees up budget for extension of benefits package in further deepening financial risk protection [1]. The UCS covers certain high-cost life-saving interventions such as antiretroviral treatment for HIV in 2006 and renal replacement therapy in 2009 despite the cost ineffectiveness of chronic dialysis, but because the cost of dialysis is prohibitively high and can be catastrophic to households [17, 18]. Not only high-cost treatments but the UCS also covers long-term community interventions such as treatment for psychotic diseases, certain items of Thai traditional medicine, and seasonal influenza vaccination [19]. Figure 6 describes the chronological events of extension of the UCS benefits package to high cost interventions, all subject to rigorous health technology assessment.
Fourthly, Thailand has developed local capacities to generate evidence on health technology assessment, which was rigorously applied to the annual review for inclusion of new health interventions into the UCS benefits package. The benchmark for inclusion of cost-effective interventions is the incremental cost effectiveness ratio equal to one Gross Domestic Product (GDP) per capita for one Quality Adjusted Life Year gain from the intervention. Other criteria for decision include budget impact within fiscal capacity to fund new interventions and readiness of health systems to deliver the interventions equitably [20]. Health technology assessment helps improve efficiency of resource use and minimize waste from spending on interventions that are not cost-effective.
Fifthly, capitation payment requires the UCS members to register with a primary health care network, which consists of one district hospital and 10–12 sub-district health centres, serving about 50,000 people in the district catchment area [1, 3]. The gate keeping function of primary healthcare contractor network gains efficiency and provides better continuity of care for non-communicable diseases (NCD) in particular. Better access to primary health care network with assured referral to provincial tertiary care hospitals when clinically indicated results in adequate use of services and low level of OOP and transport cost by households [3, 18].
Lastly, the full geographical coverage of over 9,800 sub-district health centres in all 8,860 sub-districts, and 780 district hospitals and 116 provincial/regional hospitals in all 998 districts and 77 provinces throughout the country is the solid platform for equitable access to the comprehensive set of benefits package which result in favourable financial risk protection at sub-national level [3, 21].
Certain limitations remain. Firstly, data on OOP paid by households is an aggregate figure which did not break down by types of health facilities which hampers further detail breakdown analysis by types of health facility. Secondly, as the unit of analysis is ‘household’ not ‘individual’, therefore per capita expenditure was estimated from total household OOP divided by number of household members without adjustment; and this cannot perfectly represent the real data collection from individual household member. Lastly, interview survey is prone to recall bias which may undermine the accuracy of reported data by household members. Also, there was a possibility that the head of a household, who is the respondent to NHSO surveys, may not catch up with the real health spending by other household members.